Neurophonic is developing an innovative treatment for tinnitus using targeted neurostimulation. Their approach aims to alleviate symptoms by modulating neural activity associated with the condition.
Funding
Funding not disclosed
Founders
Product
Problem
Tinnitus, affecting 10-15% of the global population, presents a significant challenge as conventional treatments often provide limited relief, leaving many individuals without effective solutions. Sufferers are frequently told to simply "learn to live with it," highlighting the lack of satisfactory medical interventions.
Solution
Neurophonic is developing a technology-driven treatment for tinnitus that uses bimodal neuromodulation, combining non-invasive nerve stimulation with patient-specific sound therapy, to retrain the brain and suppress the effects of tinnitus. The approach involves non-invasively training the brain to mitigate the debilitating effects of tinnitus, aiming to restore tranquility. An initial device prototype is undergoing clinical validation through a controlled human trial. The company is refining its initial prototype towards a version tailored to the needs of tinnitus patients and is actively pursuing clinical validation and device certification from regulatory bodies such as the FDA and MDR.
Target Audience
The primary target audience includes individuals suffering from tinnitus and the medical professionals and caregivers who treat them.
Features
- Bimodal neuromodulation combining non-invasive nerve stimulation with patient-specific sound therapy.
- Non-invasive brain retraining to suppress the effects of tinnitus.
- Initial device prototype undergoing clinical validation.
- Technology is being refined towards a first official version tailored to the needs of tinnitus patients.